ArticleEchocardiography (Mount Kisco, N.Y.)2025
Echocardiographic Markers of Prognosis in Patients Undergoing Ventricular Arrhythmia Ablation.
Article in Echocardiography (Mount Kisco, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Echocardiographic Markers of Prognosis in Patients Undergoing Ventricular Arrhythmia Ablation.Echocardiography (Mount Kisco, N.Y.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRadiofrequency catheter ablation (RFA) plays an increasing role in the treatment of ventricular arrhythmias (VAs). This study aimed to evaluate the echocardiographic and clinical characteristics of patients undergoing first-time RFA for VAs and to identify risk factors associated with VA recurrence, implantable cardioverter-defibrillator (ICD) therapy, and mortality.
methodsWe studied patients scheduled for first-time RFA for VAs from 2011 to 2022 with available transthoracic echocardiography before the procedure. The primary outcome was defined as VA recurrence, and the secondary outcome was defined as appropriate ICD therapy and mortality. Uni- and multivariable Cox hazards regression models were used to assess the prognostic value of cardiac structure and function by echocardiography.
resultsA total of 218 patients (mean age 61 years [±15], 62% men, mean LVEF 51% [IQR: 44; 57]) underwent RFA during the study period. Of these, 90 patients (41%) had VA recurrence while 52 patients (24%) developed the secondary outcome during a median follow-up time of 3.1 years (IQR: 1.1; 6.7 years). Patients with ventricular tachycardia had significantly more right-and left ventricular (LV) dysfunction, compared to patients with premature ventricular contractions. No echocardiographic measures were associated with VA recurrence, while several echocardiographic measures were associated with the secondary outcome. LV mass index, LV ejection fraction, global longitudinal strain, and VA recurrence showed the highest predictive values of the secondary outcome.
conclusionIn patients undergoing RFA for VAs, several echocardiographic measures may identify patients at risk of an adverse outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.